Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-05-30
1998-04-21
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546199, 5483087, 5483101, 548494, 514388, 514322, 514419, C07D23512, A61K 31415
Patent
active
057418047
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/US93/11779 filed Dec. 1, 1993.
FIELD OF THE INVENTION
This invention relates to novel bicyclic compounds which inhibit platelet aggregation, pharmaceutical compositions containing the compounds and methods of using the compounds.
BACKGROUND OF THE INVENTION
Platelet aggregation is believed to be mediated primarily through the fibrinogen receptor, or GPIIb-IIIa platelet receptor complex, which is a member of a family of adhesion receptors referred to as integrins. It has been found that frequently the natural ligands of integrin receptors are proteins which contain an Arg--Gly--Asp sequence (RGD in single letter amino acid code). Von Willebrand factor and fibrinogen, which are considered to be natural ligands for the GPIIb-IIIa receptor, possess an RGD sequence in their primary structure. Functionally, these proteins are able to bind and crosslink GPIIb-IIIa receptors on adjacent platelets and thereby effect aggregation of platelets.
Fibronectin, vitronectin and thrombospondin are RGD-containing proteins which have also been demonstrated to bind to GPIIb-IIIa. Fibronectin is found in plasma and as a structural protein in the intracellular matrix. Binding between the structural proteins and GPIIb-IIIa may function to cause platelets to adhere to damaged vessel walls.
Linear and cyclic peptides which bind to vitronectin and contain an RGD sequence are disclosed in WO 89/05150 (PCT US88/04403). EP 0 275 748 discloses linear tetra- to hexapeptides and cyclic hexa- to octapeptides which bind to the GPIIb-IIIa receptor and inhibit platelet aggregation. Other linear and cyclic peptides, the disclosure of which are incorporated herein by reference, are reported in EP-A 0 341 915. However, the peptide like structures of such inhibitors often pose problems, such as in drug delivery, metabolic stability and selectivity. Inhibitors of the fibrinogen receptor which are not constructed of natural amino acid sequences are disclosed in EP-A 0 372A86, EP-A 0 381 033 and EP-A 0 478 363. WO 92/07568 (PCT/US91/08166) discloses fibrinogen receptor antagonism which mimic a conformational .gamma.-turn in the RGD sequence by forming a monocyclic seven-membered ting structure. There remains a need, however, for novel fibrinogen receptor antagonists (e.g. inhibitors of the GPIIb-IIIa protein) which have potent in vivo and in vitro effects and lack the peptide backbone structure of amino acid sequences.
The present invention discloses novel bicyclic compounds, including benzimidazoles. These compounds inhibit binding to the GPIIb-IIIa receptor and inhibit platelet aggregation.
SUMMARY OF THE INVENTION
In one aspect this invention is a bicyclic compound comprising a substituted six-membered ring fused to a substituted five-membered ring as described hereinafter in formula (I).
This invention is also a pharmaceutical composition for inhibiting platelet aggregation or clot formation, which comprises a compound of formula (I) and a pharmaceutically acceptable carrier.
This invention is further a method for inhibiting platelet aggregation in a mammal in need thereof, which comprises internally administering an effective amount of a compound of formula (I).
In another aspect, this invention provides a method for inhibiting reocclusion of an artery or vein in a mammal following fibrinolytic therapy, which comprises internally administering an effective amount of a fibrinolytic agent and a compound of formula (I). This invention is also a method for treating stroke, transient ischemia attacks, myocardial infarction, or atherosclerosis.
DETAILED DESCRIPTION OF THE INVENTION
This invention discloses novel bicyclic compounds which inhibit platelet aggregation. The novel bicyclic compounds comprise a five-membered ring fused to an aromatic six membered ring and having a nitrogen-containing substituent on the six membered ring and an aliphatic substituent, preferably containing an acidic moiety, on the five membered ring. The five membered ring may contain heteroatoms, such as nitrogen, oxygen and sulf
REFERENCES:
patent: 4634783 (1987-01-01), Fujii et al.
patent: 5272167 (1993-12-01), Girijavallabhan et al.
Keenan Richard McCulloch
Miller William Henry
Lentz Edward T.
McCarthy Mary E.
Richter Johann
SmithKline Beecham Corporation
Stockton Laura L.
LandOfFree
Substituted benzimazoles which inhibit platelet aggrecation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted benzimazoles which inhibit platelet aggrecation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted benzimazoles which inhibit platelet aggrecation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2057776